Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Van Andel Institute Establishes Global Epigenetics Research Hub

Published: Wednesday, February 26, 2014
Last Updated: Wednesday, February 26, 2014
Bookmark and Share
Institute announces the establishment of a global epigenetics research hub, tapping into a hot-button research topic responsible for new and innovative approaches to personalized cancer therapy.

Epigenetics is widely regarded as the most significant new area of cancer research; it is the study of heritable changes in gene activity which are not caused by changes in the DNA sequence. The term epigenetics literally means “above” or “on top of” genetics, referring to external modifications to DNA that can turn genes “on” or “off.”

Leading this effort is Peter A. Jones Ph.D., D.Sc., Director of Research, Chief Scientific Officer of Van Andel Research Institute. Dr. Jones is a renowned researcher with more than 40 years’ experience in academia in the field of biomolecular research. Dr. Jones’ recent research has focused on epigenetics and how epigenetic therapies might benefit those living with cancer. He is based in the global headquarters of Van Andel Institute in Grand Rapids, Michigan and is driving the focus of epigenetic research among the Institute’s research partners in the U.S., U.K., Europe, Asia and around the world.

Dr. Jones’ aggressive blueprint for progress includes developing a consortium of five academic institutions – four in the U.S. and one abroad – which will carry on the work of developing epigenetic therapies that can be applied to human beings. The concept of collaboration plays a primary role in Dr. Jones’ strategy of creating a focus on epigenetics at the Institute. It is a notion that Dr. Jones has cultivated throughout his career, working alongside diverse teams of researchers, geneticists, chemists, oncologists, surgeons and assorted specialists.

“With the appointment of Dr. Jones, a visionary leader in biomedical research, Van Andel Institute is now a global stronghouse in epigenetics, one of the most significant fields in cancer research,” said David Van Andel, Chairman and CEO, Van Andel Institute. “We are embracing this field of study, and will extol epigenetics to a hurting world that is hungry for answers. At Van Andel Institute, we bank on sound science that precedes us, and embrace others who share our vision, and that includes ‘disruptors’ who are not afraid to say that we are impatient for new breakthroughs. Paired with our translational research that is speeding the delivery of new therapies from research bench to bedside, the establishment of an epigenetics hub with Dr. Jones at the helm will impact millions of lives, developing new epigenetic therapies for cancer and neurodegenerative diseases.”

Dr. Jones plans to bolster the Institute’s impressive research portfolio in cancer, neurodegenerative and other diseases as he continues his translational research in epigenetics. “Van Andel Institute is dedicated to changing the course of biomedical research and as I lead our new epigenetics hub, I have already begun to build a robust clinical program, am recruiting outstanding scientists and plan to continue to ensure exceptional science,” said Dr. Jones.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Prognostic Role Found for miR-21 Expression in Triple-Negative Breast Cancer
Findings suggest measurement of changes in the tumor microenvironment are important in this heterogeneous group.
Wednesday, December 03, 2014
Van Andel Research Institute Findings Provide More Complete Picture of Kidney Cancer
Two recent studies distinguish cancer subtypes and provide promising new drug targets, which could pave the way for better treatments.
Tuesday, January 03, 2012
Determining the Structure of Nuclear Receptor has Implications for a Host of Diseases
VAI finding provides a basis for drug design for diseases related to heart and blood vessel development, human embryo development and female infertility.
Thursday, September 18, 2008
Scientific News
New CAR T Cell Therapy Using Double Target Aimed at Solid Tumors
Researchers at Penn University have described how antibody, carbohydrate combination could apply to range of cancer types.
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Alzheimer's Genetics Point To New Research Direction
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
The Epigenetic Influences of Chronic Pain
Researchers at Drexel University College of Medicine are aiming to identify new molecular mechanisms involved in pain.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!